The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Open accessAbstract
Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040.Methods: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality.Results: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85).Conclusion: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationThe prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Self-citationYounossi, Z., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V. W., Negro, F., Yilmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 806
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Self-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Noureddin, M., Vipani, A., Bresee, C., Todo, T., Kim, I. K., Alkhouri, N., Setiawan, V. W., Tran, T., Ayoub, W. S., Lu, S. C., et al. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0088-6 · Cited by 578
Younossi, Z. M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., & Henry, L. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 576
Self-citationNonalcoholic Fatty Liver Disease in Lean Individuals in the United States
Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., & Srishord, M. (2012) · Medicine · doi:10.1097/md.0b013e3182779d49 · Cited by 559
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 335
Golabi, P., Paik, J. M., AlQahtani, S., Younossi, Y., Tuncer, G., & Younossi, Z. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.022 · Cited by 259
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Alswat, K., Aljumah, A. A., Sanai, F. M., Abaalkhail, F. A., Alghamdi, M., Hamoudi, W. A., Khathlan, A. A., Quraishi, H. A., Rifai, A. A., Zaabi, M. A., et al. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_122_18 · Cited by 157
Li, J., Ha, A. Y., Rui, F., Zou, B., Yang, H., Xue, Q. C., Hu, X., Xu, Y., Henry, L. L., Barakat, M. T., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17096 · Cited by 137
Self-citationNonalcoholic fatty liver disease burden: Australia, 2019–2030
Adams, L. A., Roberts, S. K., Strasser, S. I., Mahady, S. E., Powell, E. E., Estes, C., Razavi, H. A., & George, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15009 · Cited by 135
Golabi, P., Paik, J. M., Fukui, N., Locklear, C. T., de Avilla, L., & Younossi, Z. M. (2018) · Clinical Diabetes · doi:10.2337/cd18-0026 · Cited by 132
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
Alqahtani, S. A., Paik, J. M., Biswas, R., Arshad, T., Henry, L. L., & Younossi, Z. M. (2021) · Hepatology Communications · doi:10.1002/hep4.1765 · Cited by 131
Self-citationA Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
Younossi, Z. M., Ong, J. P., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M.-H., Fan, J.-G., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.048 · Cited by 115
Self-citationWu, Y., Zheng, Q., Zou, B., Yeo, Y. H., Li, X., Li, J., Xie, X., Feng, Y., Stave, C. D., Zhu, Q., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10023-3 · Cited by 109
Self-citationImpact of the COVID-19 pandemic on liver disease-related mortality rates in the United States
Gao, X., Lv, F., He, X., Zhao, Y., Liu, Y., Zu, J., Henry, L. L., Wang, J., Yeo, Y. H., Ji, F., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.028 · Cited by 109
Self-citationMortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
Golabi, P., Paik, J. M., Arshad, T., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology Communications · doi:10.1002/hep4.1534 · Cited by 108
Arshad, T., Paik, J. M., Biswas, R., Alqahtani, S. A., Henry, L. L., & Younossi, Z. M. (2021) · Hepatology Communications · doi:10.1002/hep4.1760 · Cited by 97
Self-citationPaik, J. M., Golabi, P., Younossi, Y., Srishord, M., Mishra, A., & Younossi, Z. (2020) · Hepatology Communications · doi:10.1002/hep4.1599 · Cited by 93
Le, M. H., Yeo, Y. H., Cheung, R. C., Wong, V. W., & Nguyen, M. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13035 · Cited by 91
Self-citationBurden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study
Swain, M. G., Ramji, A. S., Patel, K., Sebastiani, G., Shaheen, A. A., Tam, E., Marotta, P., Elkhashab, M., BAJAJ, H. S., Estes, C., et al. (2020) · CMAJ Open · doi:10.9778/cmajo.20190212 · Cited by 89
Ng, C. H., Huang, D. Q., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0070 · Cited by 82
Self-citationPediatric Non-Alcoholic Fatty Liver Disease
Bush, H., Golabi, P., & Younossi, Z. M. (2017) · Children · doi:10.3390/children4060048 · Cited by 78
Golabi, P., Bush, H., Stepanova, M., Locklear, C. T., Jacobson, I. M., Mishra, A., Trimble, G., Erario, M., Venkatesan, C., Younossi, I. M., et al. (2018) · Medicine · doi:10.1097/md.0000000000011518 · Cited by 73
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0187 · Cited by 69
A Fundamental Limitation of Markov Models
DelSole, T. (2000) · Journal of the Atmospheric Sciences · doi:10.1175/1520-0469(2000)057<2158:aflomm>2.0.co;2 · Cited by 64
Wang, J., Wu, A. H., Stanczyk, F. Z., Porcel, J., Noureddin, M., Terrault, N. A., Wilkens, L. R., & Setiawan, V. W. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.012 · Cited by 60
Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
Arshad, T., Golabi, P., Paik, J. M., Mishra, A., & Younossi, Z. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1285 · Cited by 58
Paik, J. M., Golabi, P., Younossi, Y., Saleh, N., Nhyira, A., & Younossi, Z. (2021) · Hepatology Communications · doi:10.1002/hep4.1673 · Cited by 39
Younossi, Z. M., Stepanova, M., Noureddin, M., Kowdley, K. V., Strasser, S. I., Kohli, A., Ruane, P. J., Shiffman, M. L., Sheikh, A. M., Gunn, N., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1710 · Cited by 37
Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
Younossi, Z. M., & Henry, L. L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.010 · Cited by 36
Self-citationTherapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Lee, H. A., Chang, Y. W., Sung, P. S., Yoon, E. L., Lee, H. W., Yoo, J., Lee, Y., An, J., Song, D. S., Cho, Y. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0186 · Cited by 32
Nonalcoholic fatty liver disease burden – Switzerland 2018–2030
Goossens, N., Bellentani, S., Cerny, A., Dufour, J., Jornayvaz, F. R., Mertens, J. C., Moriggia, A., Muellhaupt, B., Negro, F., Razavi, H. A., et al. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20152 · Cited by 29
Research works printed but not linked: 3
- Current smokers
- Yeo, 2022, Trends of cirrhosis-related mortality in the United States during the COVID-19 pandemic: a cohort study
- Ng, 2022, NAFLD versus MAFLD: prevalence, outcomes and implications of a change in name
Cited by
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
Self-citationGlobal Incidence and Prevalence of Nonalcoholic Fatty Liver Disease
Teng, M. L., Ng, C. H., Huang, D. Q., Chan, K. E., Tan, D. J., Lim, W. H., Yang, J. D., Tan, E., & Muthiah, M. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0365 · Cited by 727
Koliaki, C., Dalamaga, M., & Liatis, S. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00527-y · Cited by 418
Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.006 · Cited by 416
Lifestyle interventions in nonalcoholic fatty liver disease
Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00800-4 · Cited by 281
Self-citation
Metadata
- Authors
- Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H.
- Venue
- Clinical and Molecular Hepatology
- Published
- 2022-10-01
- Volume
- 28
- Issue
- 4
- Pages
- 841-850
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- OpenAlex
- W4296331184
- Cited by
- 357
- References
- 41
- FWCI
- 37.35
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Funders
- Pfizer
- Enanta
- Gilead Foundation
- CurveBio
- Exact Sciences
- Helio Health
- Glycotest
- National Cancer Institute
- B.K. Kee Foundation
- Vir Biotech
- Siemens Healthineers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.